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Background: Kidney injury molecule-1 (KIM-1), a recently discovered transmembrane protein, is expressed in
dedifferentiated proximal renal tubular epithelial cells in damaged regions. Kidney injury early detection in diabetic
patients has great importance for therapy and prognosis. Therefore, the aim of the present study is to predict,
validate and evaluate the presence of KIM-1 in kidney inflammation, dialectic and diabetic nephropathy diseases.
Methods: Sixty males and females subjects (30-52 years) were selected for this study. They were subdivided into
three main groups; kidney injury, diabetic and diabetic nephropathy patients. The work was extended to evaluate
KIM-1 after treatment of each disease.
Results: The results revealed significant elevation of KIM-1 in the diseased groups and a noticeable reduction after
treatment. Diabetic nephropathy recorded the highest KIM-1 level than the AKI state or the diabetic patients. We
noticed an association between KIM-1 and sex and a positive correlation (p < 0.0001) with the disease severity.
Conclusions: In conclusion, urinary KIM-1 has been reported to be a noninvasive, rapid, sensitive, and reproducible
biomarker to detect early kidney injury. We speculate that KIM-1 is expected to be a therapeutic target for kidney injury.
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Renal epithelial cell injury is the feature of many acute
and chronic renal diseases. Kidney injury molecule-1
(KIM-1), a recently discovered transmembrane tubular
protein, is markedly induced in renal injury including
acute kidney injury (AKI) and chronic kidney disease
(CKD) [1-4]. In renal patients, KIM-1 is up-regulated in
a variety of conditions including ischemia, nephrotoxic
drugs, CKD, and acute/chronic renal transplant dysfunc-
tion. Many studies indicate that KIM-1 is a sensitive and
specific marker of kidney injury as well as a predictor of
prognosis [5,6]. There are many characteristics of KIM-1
making it an ideal biomarker for kidney injury. For
example, KIM-1 is not expressed in normal kidney but
specifically expressed in injured proximal tubular cells,
and such an expression can persist until the damaged
cells have completely recovered. Moreover, the rapid* Correspondence: manal_hamed@yahoo.com
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article, unless otherwise stated.and integrated cleavage of its ectodomain into the
lumens of kidney tubules can make it detectable in
urine [7]. Urinary KIM-1 level is closely related to
tissue KIM-1 and correlates with the severity of renal
damage, so quantitation of urinary KIM-1 is likely to be
a noninvasive and sensitive method for the evaluation of
kidney injury and even for monitoring the therapeutic
effects of kidney injury [8].
A long duration of elevated blood glucose levels (i.e.
poorly controlled diabetes) is considered the major
underlying mechanism causing diabetic nephropathy and
chronic kidney disease [9]. Interestingly, the interplay
between a disturbed glucose metabolism and kidney
damage appears to be bi-directional; individuals with
micro-albuminuria are at an increased risk of developing
diabetes [10]. Other aspects of glucometabolic derange-
ments than diabetes have also been suggested to be of im
portance for the development of kidney damage. In par-
ticular, insulin resistance has been shown to be closely
associated with the two major indices of kidney damageCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tion rate (GFR) and urinary albumin/creatinine ratio
(ACR), even prior to the development of diabetes [11].
Both GFR and ACR have limitations as biomarkers as they
both mainly reflect an underlying disease process that
already is well established [7,12]. In order to better iden-
tify individuals with an increased risk for chronic kid-
ney disease, there is need for biomarkers that may
detect early signs of kidney damage. A recent study
reported elevated KIM-1 levels in diabetes patients with
normo-albuminuria [13], indicating that renal tubular
damage may be involved in early stages of the develop-
ment of diabetic nephropathy.
The aim of the present study is to predict and evaluate
the KIM-1 level in patients with kidney inflammation,
early stage of diabetic nephropathy and diabetic patients
with detectable kidney inflammation. In addition, the
role of KIM-1 to be consider as a diagnostic tool after
treatment of such disease.Materials and methods
Subjects
Participants were recruited from Kasr Al-Aini Clinics at
Kasr Al-Aini university hospital, Cairo, Egypt. This research
was performed on 60 males and 60 females aged 30-52
years. Each sex was classified into four main groups (15
subjects each). Group 1 served as healthy control. Group 2
was patients with kidney inflammation (KI). Subgroup 2
was the same patients of group 2 and undergoes the clas-
sical treatment of inflamed kidney. Group 3 was diabetic
patients (insulin independent). Subgroup 3 was the same
members of group 3 and treated for diabetes. Group 4
was patients with diabetic nephropathy. Subgroup 4
was diabetic nephropathy patients of group 4 and treated
for diabetes and kidney inflammation.Clinical examination and diagnosis
Serum and urine samples were collected from healthy
subjects who attending to Kasr Al-Aini Clinics, Cairo,
Egypt for regular checkup. Individuals were informed of
the testing to be performed and only the specified test-
ing was performed on the collected reference specimens.
Analyses were conducted with the full respect for the
individual’s right to confidentiality. Information regarding
their age and gender was also collected to estimate the
glomerular filtration rate (GFR), urine and serum creatin-
ine as well as blood glucose level in all the studied groups.
KIM-1 patients, diabetic and diabetic nephropathy
patients were diagnosed according to the reference
values, where diabetes was defined as fasting plasma
glucose ≥7.0 mmol/l (≥126 mg/dl) [14], glomerular filtera-
tion rate (GFR) <60 mL/min/1.73 m2 [15] and serum
creatinine level > 0.5 mg/dL [1].Treatments
AKI patients were treated with 500 mg of Cpirofloxacin
(Amriya Pharm Industries Co., Egypt) twice daily for
7 days and Urosolvine sachets (Nile Pharm Co., Egypt)
three times daily. Diabetic patients treated with 1 g of
Glucophage (Mina Pharm Co., Egypt) tablets daily.
Diabetic nephropathy patients treated with the three
above drugs for 7 days before the biochemical determi-
nations of KIM-1.
Sample collections for KIM-1 determination
Urine samples were allowed to sit at room temperature
for 30 minutes to sediment, and the supernatant was
aliquoted and stored at -80°C until analysis.
KIM-1 determination
Construction of KIM-1 sandwich ELISA (R&D Cat#
DY1750, Minneapolis, MN): The wells of Nunc-Maxisorp
EIA plates were coated by diluting the capture antibody
(72 μg/mL) to a working concentration of 0.4 μg/mL in
PBS with 100 μL in each well. The plate was sealed and
incubated overnight at room temperature. Each well was
aspirated and washed using an automated microplate
washer (Bio-Tek) with 400 μL of Wash Buffer (0.05%
Tween-20 in PBS), repeating the process two times for a
total of three washes. The plates were blocked by adding
300 μL of reagent diluent (1% BSA in PBS, 0.2 μm filtered)
to each well and incubated at room temperature for
2 hours. After washing as in the previous step, 100 μL of
standard recombinant human KIM-1 (0-2000 pg/mL),
control, and urine sample was pipette to the designated
well, covered with an adhesive strip, and placed on the
orbital shaker at 400 rpm at room temperature for 2 hours.
The plate was washed using the same wash protocol as
before, and 100 μL of the biotinylated goat anti-human
KIM-1 detection antibody diluted in reagent diluent to a
working concentration of 400 ng/mL was added to each
well. The plate was covered with a new adhesive strip,
incubated at room temperature for 2 hours with contin-
ued shaking at 400 rpm. Washing step was repeated and
100 μL of streptavidin-HRP diluted to a working dilution
was added to each well. The plate was protected from
light, covered with a new adhesive strip, shaken at
400 rpm, and incubated at room temperature for
20 minutes. After washing, 100 μL substrate solution
was added to all wells, protected from light, covered
with an adhesive strip, shaken at 400 rpm, and incubated
at room temperature for 7 minutes. The reaction was
stopped by adding 50 μL of stop solution to all wells. The
absorbance was measured using a plate reader (BioTek
Elx800) at 450 nm with an absorbance correction at
540 nm. The urinary KIM-1 concentration was calculated
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Figure 1 % changes of KIM-1 in males patients with inflamed kidney, diabetes and inflamed kidney with diabetes.
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Results were expressed as mean ± SD of 15 subjects in
each group. Results were evaluated by using one way
analysis of variance test (ANOVA), Costat Software
Computer Program with least significance difference
(LSD) between groups at p < 0.05. Pearson’s test was
done to detect correlation value with each parameter.
Human rights
All procedures followed were in accordance with the
ethical standards of the Medical Ethical Committee at
National Research Centre, Cairo, Egypt and with the
Helsinki Declaration of 1975, as revised in 2008.
Informed consent
Informed consent was obtained from all patients for
being included in this study.
Results and discussion
The ability of biomarkers to predict kidney inflammation
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Figure 2 KIM-1 in females patients with inflamed kidney, diabetes ansettings. For a sound interpretation of the reported results,
it is important to realize that the studies present a mix-
ture of ‘AKI diagnosis confirmation’ in patients with
established AKI and ‘AKI early prediction’ in patients
with developing AKI. AKI has been defined as a rapid
decline in glomerular filtration rate that occurs over
hours or days [7]. For the clinical application of a new
biomarker, it should prove to be more accurate with
earlier detectable than the current gold standard serum
creatinine, which implies ‘early prediction’ only [16]. The
present results revealed significant increase in KIM-1 by
935.70 and 1854.05% in early detected inflamed kidney
of males and females as compared with the control
group (Figures 1 and 2). Although the KIM-1 basal line
was higher in males 280.38 ± 51.66 pg/ml than female
147.18 ± 21.70, but it was highly detectable in females
inflamed kidney than males (Tables 1 and 2). Inflamed
kidney patient that undergo treatment recorded significant
decrease in KIM-1by 31.25% in males and 30.54% in
females as compared to the inflamed kidney patients.
Therefore, KIM-1 recorded efficiency in diminution afterInflamed kidney
Diabetes
Diabetes with inflamed kidney
dney
d inflamed kidney with diabetes.
Table 1 Kidney inflammatory molecule-1 in inflamed kidney, diabetes and inflamed kidney with diabetes in males patients
Groups Mean ± SD % of KIM-1
efficiency
Correlation between KIM-1 and disease severity
r P<
Healthy 280.38f ± 51.66 --- --- ---
Inflamed kidney 2903.09c ± 301.76 --- 1.00* 0.0001
Treated inflamed kidney 1995.80d ± 80.87 [-31.25] 323.59 0.86* 0.0010
Diabetes 1987.78d ± 169.35 --- 0.72* 0.0200
Treated diabetes 1146.56e ± 46.35 [-42.31] 300.02 0.75 0.0800
Diabetes with inflamed kidney 3855.80a ± 116.95 --- 0.94* 0.0001
Treated diabetes with inflamed kidney 3491.26b ± 112.39 [-9.45] 130.02 0.83* 0.0010
Data are expressed as mean ± SD of 15 males in each group.
Values are expressed as pg/ml.
Statistical analysis is carried out using one way analysis of variance test (ANOVA), Costat Computer Program accompanied with least significance difference
between groups (LSD) at p < 0.05.
Unshared superscript letters between groups are the significance value at p < 0.0001.
*is the significance level between the KIM-1 level and the disease severity.
Values between parentheses are percentage change over diseased group.
% of efficiency = [(mean of treated group- mean of diseased group)/mean of healthy group] × 100.
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respectively (Tables 1 and 2). We also noticed insignifi-
cant correlations between KIM-1and age, while a highly
association between KIM-1 and sex was observed re-
garding to its high expression in healthy male. Highly
positive association between KIM-1 and degree of kid-
ney inflammation was also observed. Ruangyuttikarn
et al. [17] had also proved that detection of KIM-1 by
ELISA technique gave a very high sensitivity and speci-
ficity in urine samples. In addition, KIM-1 in urine was
still stable even after the urine was frozen and thawed
for 4 cycles. The same authors added that KIM-1 more
accurate for detection of kidney inflammation that the
two conventional renal tubular dysfunction biomarkers;Table 2 Kidney inflammatory molecule-1 in inflamed kidney,
females patients
Groups Mean ± SD %
e
Healthy 147.18e ± 21.70 -
Inflamed kidney 2875.98b ± 275.72 -
Treated inflamed kidney 2497.43c ± 254.22 [-30.54] 2
Diabetes 1485.81d ± 18.50 -
Treated diabetes 1288.72d ± 36.54 [-13.16] 1
Diabetes with inflamed kidney 3806.52a ± 108.19 -
Treated diabetes with inflamed kidney 2630.16b ± 91.08 [-30.90] 1
Data are expressed as mean ± SD of 15 females in each group.
Values are expressed as pg/ml.
Statistical analysis is carried out using one way analysis of variance test (ANOVA), C
between groups (LSD) at p < 0.05.
Unshared superscript letters between groups are the significance value at p < 0.000
*is the significance level between the KIM-1 level and the disease severity.
Values between parentheses are percentage change over diseased group.
% of efficiency = [(mean of treated group- mean of diseased group)/mean of healthN-acetyl-β-Dglucosaminidase (NAG) and β2-microglobulin
(β2-MG).
Regarding to the diabetic patients in our results, we
noticed a significant increase in KIM-1in both males and
females, although these patients not recorded any sign
of kidney inflammation. The KIM-1 in male diabetic
patient was significantly increase by 608.95% (Figure 1),
while it was significantly increase by 909.51% in female
diabetic patients (Figure 2). In agreement with our
results, Chaudhary et al. [12] and Rossing [18] stated
that early renal tubular damage biomarker levels (in-
cluding urinary KIM-1 levels) are elevated in patients
with diabetes, even in those with normoalbuminuria.
Carlsson et al. [15] added that insulin sensitivity wasdiabetes and inflamed kidney with diabetes in
of KIM-1
fficiency
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KIM-1 concentrations.
Patients undergo classical diabetic treatment recorded
significant decrease in KIM-1 by 42.31% in male and
insignificant decrease in female by 13.16% as compared
with the diabetic persons. Therefore, KIM-1 was improved
after treatment by 300.02% in male and 133.91% in female
and correlate positively with the high glucose level
(Tables 1 and 2).
Concerning with diabetic nephropathy patients, the
present study revealed significant increase in KIM-1 in
males and females by 1275.20 and 2486.30%, respectively
as compared with the healthy group (Figures 1 and 2).
We noticed that KIM-1 level was more pronounced in
females of diabetic nephropathy than in males. Positive
correlations between KIM-1 level and both sex and
severity of the disease were also recorded. In parallel
with our finding Carlsson et al. [15] found significant
elevation of KIM-1 in insulin resistance elderly indi-
viduals. Impaired insulin sensitivity and compensatory
hyperinsuli- nemia have been suggested to contribute to
development of renal injury by promotion of mitogenic
and fibrotic processes via different pathophysiologic
pathways such as activation of insulin-like growth factor-
1, transforming growth factor-b, endothelin-1, and the
renin–angiotensin–aldosterone system [19]. Moreover,
insulin resistance is closely associated with oxidative
stress [20], pro-inflammatory cytokines and adipo-kines
[21], which also could promote renal injury. But the
opposite chain of events is also possible; an increased
inflammatory activity due to ongoing kidney damage could
also impair insulin sensitivity [22]. Tubulointer- stitial
injury is present in all forms of chronic kidney disease and
is thought to be a better predictor of disease progression
and long-term prognosis than is the severity of damage to
glomeruli [23]. By measuring KIM-1, this “tubular phase”
of renal damage could be detected before the development
of albuminuria, the currently used marker of early diabetic
nephropathy [18,19].
We noticed that the KIM-1 in diabetic nephropathy
patients recorded the highest level than in kidney inflam-
mation state alone. This is may be due to the severity state
of kidney inflammation associated with the diabetic state.
Diabetic patients only may not have a complication as kid-
ney inflammation or it may not reached to the diagnosis
level which give an additional support to use KIM-1 as a
diagnostic tool.
In the present study, treatment of diabetic nephropathy
patients showed significant decrease in KIM-1 level by
9.45% and 30.90% in male and females, respectively as
compared with the diabetic nephropathy groups (Tables 1
and 2). Therefore, KIM-1 recorded efficiency in dimin-
ution after treatment by 130.02% and 119.82% in males
and females, respectively. Vaidya et al. [24] mentioned thatregression of diabetic nephropathy after treatment has
been shown to be associated with reduced levels of urinary
KIM-1 which confirmed our results.
In conclusion, KIM-1 might be a specific predictor for
early detection of kidney inflammation, in diabetic disease
where no sign of kidney inflammation was persisted, and
in diabetic nephropathy disease. KIM-1 is expected to be a
therapeutic target for kidney injury. KIM-1 and its poten-
tial value need to be validated in large studies and across a
broader scope of clinical settings. Due to the relatively
limited number of cases in this study, further studies are
needed for accurately determine the use of KIM-1 as a
biomarker, as the small sample size makes it difficult to
evaluate its validity.
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